Next, to determine the individual and/or combined effects of DVL2 and HER2 inhibition on cell-cycle phases in HER2-amplified breast cancer cell lines, we studied the different stages in actively proliferating (live) SKBR3 and BT474 cells stably expressing NTC vs. shDVL2 and treated them with 1 nM Nert or DMSO control (Fig. 3E-F). Here, ERBB2 is linked to breast carcinoma.